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Abstract
Background: We conducted a systematic review of evidence from randomized controlled trials to answer the
following research question: What are the relative effects of different classes of antihypertensive drugs in reducing
the incidence of cardiovascular disease outcomes for healthy people at risk of cardiovascular disease?
Methods: We searched MEDLINE, EMBASE, AMED (up to February 2011) and CENTRAL (up to May 2009), and
reference lists in recent systematic reviews. Titles and abstracts were assessed for relevance and those potentially
fulfilling our inclusion criteria were then assessed in full text. Two reviewers made independent assessments at
each step. We selected the following main outcomes: total mortality, myocardial infarction and stroke. We also
report on angina, heart failure and incidence of diabetes. We conducted a multiple treatments meta-analysis using
random-effects models. We assessed the quality of the evidence using the GRADE-instrument.
Results: We included 25 trials. Overall, the results were mixed, with few significant dif-ferences, and with no drug-
class standing out as superior across multiple outcomes. The only significant finding for total mortality based on
moderate to high quality evidence was that beta-blockers (atenolol) were inferior to angiotensin receptor blockers
(ARB) (relative risk (RR) 1.14; 95% credibility interval (CrI) 1.02 to 1.28). Angiotensin converting enzyme (ACE)-
inhibitors came out inferior to calcium-channel blockers (CCB) regarding stroke-risk (RR 1.19; 1.03 to 1.38), but
superior regarding risk of heart failure (RR 0.82; 0.69 to 0.94), both based on moderate quality evidence. Diuretics
reduced the risk of myocardial infarction compared to beta-blockers (RR 0.82; 0.68 to 0.98), and lowered the risk of
heart failure compared to CCB (RR 0.73; 0.62 to 0.84), beta-blockers (RR 0.73; 0.54 to 0.96), and alpha-blockers (RR
0.51; 0.40 to 0.64). The risk of diabetes increased with diuretics compared to ACE-inhibitors (RR 1.43; 1.12 to 1.83)
and CCB (RR 1.27; 1.05 to 1.57).
Conclusion: Based on the available evidence, there seems to be little or no difference between commonly used
blood pressure lowering medications for primary prevention of cardiovascular disease. Beta-blockers (atenolol) and
alpha-blockers may not be first-choice drugs as they were the only drug-classes that were not significantly superior
to any other, for any outcomes.
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Rationale
Cardiovascular diseases are a major public health challenge,
representing 10% of the global burden of disease [1]. The
annual number of deaths caused by cardiovascular disease
is expected to rise by more than 33% over the coming two
or three decades [2]. Hypertension is among the most
important modifiable risk-factors for cardiovascular dis-
eases [3]. Meta-analyses of placebo-controlled trials of anti-
hypertensive medication have shown that such treatment
can prevent, or postpone myocardial infarction and stroke
[4]. But the key question remains: Which of the many
available types of blood pressure lowering drugs is the
better choice as first-line medication?
Several clinical trials and systematic reviews have
addressed this issue, but have failed to convincingly show
t h a to n eo rm o r ed r u g - c l a s s e sa r es u p e r i o rt ot h eo t h e r s
[5-9]. Still, controversy remains about possible important
differences between the various drugs. The findings from
the alpha-blocker arm of the ALLHAT-trial a decade ago
[10], and reviews in recent years assessing the effective-
ness of beta-blocking agents [11,12] cast doubt about the
assumption that all antihypertensive drugs are equally
effective with regards to cardiovascular disease preven-
tion. Also, recent systematic reviews have found poten-
tially important differences regarding their effectiveness
for some specific outcomes [13,14].
Systematic reviews of randomized controlled trials
comparing different drugs provide evidence for decisions
about choice of antihypertensive medication. Unfortu-
nately, direct comparative studies are lacking for many of
the competing drug-classes. Conventional meta-analyses
of antihypertensive medication, therefore, typically pro-
vide comparative effectiveness estimates for only some
drug-comparisons, that is, those that have been tested
head-to-head in clinical trials. However, a decision maker
would want to have effect-estimates for as many compar-
isons as possible, preferably with a ranking of the various
drugs. Multiple treatments (network) meta-analyses pro-
vide this by utilizing indirect comparisons, making it pos-
sible to estimate the comparative effectiveness of drugs
that have not been tested directly in clinical trials
[8,13,14].
The most recent systematic review addressing several
of the most clinically important outcomes and using
multiple treatments meta-analysis of antihypertensive
drug therapy was published by Psaty and colleagues in
2003 [8]. An update is warranted to reflect the current
evidence-base in the field and to address some short-
comings of the earlier review, for example, that the
authors neither explicitly assessed the risk of bias in the
included studies, nor graded the quality of the overall
body of evidence.
A broad systematic review of various interventions for
primary prevention of cardiovascular diseases was
recently requested by the Norwegian Directorate for
Health [15,16]. The current paper is an updated and
substantially revised version of that report’s section on
antihypertensive treatment.
Objectives
Our study was designed to answer the following
research question: What are the relative effects of differ-
ent classes of antihypertensive drugs in reducing the
incidence of cardiovascular disease outcomes for healthy
people at risk of cardiovascular disease?
Methods
Protocol
Methods for this review were specified in advance, and
registered in the PROSPERO-database [17].
Eligibility criteria
We only included randomized controlled trials compar-
ing one or more drugs against each other, or no active
treatment. Since our focus was on primary prevention,
that is, the participants should be free from cardiovascu-
lar disease, we pragmatically excluded trials where more
than half the participants had had a myocardial infarc-
tion, stroke or other significant cardiovascular event.
We also excluded studies done exclusively in selected
subgroups of patients with hypertension, for example,
patients with diabetes or microalbuminuria.
Only trials of drugs belonging to commonly used “drug-
classes” were included: Diuretics, beta-blockers, calcium-
channel blockers (CCB), angiotensin converting enzyme
inhibitors (ACE-inhibitors), angiotensin receptor blockers
(ARB), and alpha-blockers. Because we were only inter-
ested in studies of “low-dose” diuretics, we excluded trials
where the maximum dosage in the treatment protocol was
higher than the “optimal range” as proposed by the Joint
National Committee U.S. guidelines [18] and the authors
of a recent Cochrane review [19].
To be considered for inclusion, a trial had to have car-
diovascular morbidity or mortality as a primary outcome,
either explicitly stated by the authors or based on our
judgement. In practice, this meant excluding many smal-
ler studies, typically designed to evaluate effects on surro-
gate outcomes such as blood pressure. Some of these
trials reported morbidity and mortality outcomes in addi-
tion to their primary surrogate outcome. We disregarded
these data in the belief that the information was not likely
to be important given the availability of findings from
large-scale studies with morbidity and mortality as the
main outcomes. By doing this, we also reduced the risk
of introducing certain biases in our analyses, for example,
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a greater problem with smaller studies [20].
Information sources and search
We searched MEDLINE, EMBASE, AMED (up to
February 2011) and CENTRAL (up to May 2009). See
Additional file 1 for the complete search strategy. We
also studied the reference lists in recent systematic
reviews. We did not apply any language re-strictions.
Study selection
We first assessed the relevance of titles and abstracts
that the search yielded. Secondly, potentially relevant
articles were assessed in full text. At each step two
reviewers made independent assessments.
Data collection process
Data extraction was done independently by two
reviewers using a simple, standardized form.
Data items
We extracted, where possible, data for the following main
outcomes from all the included studies: total mortality,
myocardial infarction and stroke. In addition, we
extracted data on the following outcomes: angina, heart
failure and diabetes.
Risk of bias in individual studies
Studies fulfilling our eligibility criteria were assessed for
internal validity at the study level by two reviewers inde-
pendently using a standard check list [21]. Studies were
excluded if the validity was judged as “low”.
At each step disagreements between two reviewers’
assessments were resolved through discussion, for exam-
ple, through e-mail discussions or at plenary meetings for
the whole group of reviewers.
Summary measures
We expressed the comparative effectiveness of the treat-
ments as the relative risk (RR) of an outcome, with 95%
credibility intervals (CrIs). The credibility interval is the
Bayesian analogue to confidence intervals used in tradi-
tional frequentist statistical approaches. We considered a
result “significant” if the CrI did not include RR = 1.
We also ranked the different drug-classes in terms of
their likelihood of leading to the best results for each
outcome. We chose to report on the probability that a
drug-class would be among the three best drugs for
each outcome.
Synthesis of results
The analysis was primarily based on Multiple Treatments
Meta-analysis (MTM) as described by Salanti [22]. We
used the arm-based network meta-analyses method (a
Bayesian method based on Markov Chain Monte Carlo
simulation) [22]. All MTM were performed using
Winbugs version 1.4.3 (Imperial College and MRC, UK).
We utilized random effects models. The statistical analy-
sis is based on binomial likelihoods, with vague priors for
the trial baselines, basic parameters (normal distribution
with mean 0 and standard deviation 0.0001) and the ran-
dom effects standard deviation (uniformly distributed i in
the interval 0 to 2), and takes the correlation structure
induced by multi-arm trials into account. We have used
a random effects model which follows the Normal distri-
bution with 0 as the mean.
We checked for inconsistency between direct and indir-
ect evidence by “node-splitting” [23]. We calculated the
direct and indirect estimates of effect and the correspond-
ing Bayesian “P-values” for inconsistency.
Quality-assessment of the evidence
We assessed the quality of the evidence for each outcome
for each comparison, using the GRADE-instrument (Grad-
ing of Recommendations Assessment, Development and
Evaluation - GRADE) [24]. Through this process, factors
like study limitations, inconsistency of results, indirectness
of evidence, imprecision and reporting bias are assessed.
The quality of the evidence was rated as high, moderate,
low or very low quality, reflecting the confidence we have
in the estimated effect size (see Table 1).
In line with recommendations from the GRADE Work-
ing Group by default, we graded the included evidence as
“high quality”, as all studies were randomized controlled
trials. We then downgraded when deemed appropriate.
For the comparisons where we had no direct evidence
(that is, the effect-estimates were only based on indirect
comparisons) we rated the quality as “low” unless we
found reasons to upgrade or to downgrade further.
When the findings were based on a combination of direct
and indirect evidence we elected to grade as “high qual-
ity” unless there were reasons to downgrade. The incon-
sistency of results-dimension in GRADE was only
assessed for direct comparisons (using the I
2-statistic).
The grading process was done by one reviewer (AF) and
validated by a second person.
Results
Study selection
Our search yielded 12,499 references, of which 758 were
deemed as potentially meeting our inclusion criteria,
and the complete articles studied. Among these, 25 trials
of antihypertensive medications met the inclusion cri-
teria and were of sufficient quality to be included in our
systematic review (Figure 1). A list of excluded studies is
found in Additional file 2.
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Key characteristics of included studies are presented in
Table 2 [10,25-49]. Atenolol was used in all the trials
with beta-blockers.
Eleven of the identified studies only partially addressed
our research question [30,32,34,38,41,50-55]. Four of
these trials were not direct comparisons between indivi-
dual drug-classes, but rather comparisons of one drug
against a diuretic or a beta-blocker, selected at the physi-
cian’s discretion [30,32,34,38]. We decided to include
these studies by defining “diuretics or beta-blockers” as a
separate drug-class in our analyses. Similarly, one trial
compared ARB and “conventional treatment” [41], which
we also included as a separate drug-class. Three of the
trials were comparisons between different drug combina-
tions or add-on drugs, and we decided to exclude these
[51-53]. Finally, we excluded three placebo-controlled
trials where the investigators aimed at achieving similar
blood pressure levels in both groups since in these trials
a large proportion in the placebo-group also received
active treatment, making it difficult to interpret the find-
ings for our purpose [50,54,55].
For three of the included studies [10,33,49,51], we
were in doubt whether to include or exclude, due to the
high proportion of participants with pre-existing cardio-
vascular disease. In these trials, this proportion was
probably slightly above our pragmatically selected cut-
off point of 50%. However, as we had not clearly defined
Table 1 Grades of quality of evidence in GRADE [24]
High = We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate = We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but
there is a possibility that it is substantially different.
Low = Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low = We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of
effect.
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Figure 1 Review flowchart.
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Study, year
(reference)
Comparisons (initial drug-dosages) Sample size
(total, included in
analysis)
Age
group
(years)
Follow-up (mean,
years)
VA II 1970 [43] Hydrochlorothiazide (50 mg/day) + reserpine (0.1 mg/day) +
hydralazine hydrochloride (25 mg/day) vs. placebo
380 30 to 73 3.3
Oslo hypertension
study 1980 [27]
Hydrochlorothiazide (50 mg/day) vs. no treatment 785 40 to 49 5.5
EWPHE 1985 [44] Hydrochlorothiazide (25 mg/day) + triamteren (50 mg/day) vs.
placebo
840 > 60 4.7
Coope 1986 [45] Atenolol (100 mg/day) or bendrofluazide (5 mg/day) vs. no
treatment
884 60 to 79 4.4
HAPPHY 1987 [28] Bendroflumethiazide (5 mg/day) or hydrochlorothiazide (50 mg/
day) vs. atenolol (100 mg/day) or metoprolol 200 mg/day)
6,569 40 to 64 3.8
STOP 1 1991 [46] Atenolol (50 mg/day) or HCTZ (25 mg/day) (add-on drugs:
amiloride (2.5 mg/day) or metoprolol (100 mg/day) or pindolol (5
mg/day)) vs. placebo
1,627 70 to 84 2
SHEP 1991 [26] Chlortalidone (12.5 mg/day) vs. placebo 4,736 > 60 4.5
MRC 2 1992 [29] Hydrochlorothiazide+amiloride (25 + 2.5 mg/day) vs. atenolol (50
mg/day) vs. placebo
4,396 65 to 74 5.8
SYST-EUR 1997 [47] Nitrendipine (10 mg/day) vs. placebo 4,695 > 60 4
Sun 1997 [25] Nitrendipine (10 mg/day) (starting dose: 10 mg × 3, reduced to 10
mg × 1) vs. usual care
2,080 > 15 4.7
CAPPP 1999 [30] Captopril (50 mg/day) vs. atenolol (50 to 100 mg/day) or
metoprolol (50 to 100 mg/day) or hydrochlorothiazide (25 mg/
day) or bendroflumethiazide (2.5 mg/day)
10,985 25 to 66 6.1
NICS-EH 1999 [31] Nicardipine (20 mg × 2/day) vs. Trichlormethiazide (2 mg/day) 414 ≥ 60 4.6 (nicardipine group)
and 3.9 (trichlormethia-
zide group)
STOP-2 1999 [32] Atenolol (50 mg/day) or metoprolol (100 mg/day) or pindolol (5
mg/day) or hydrochlorothiazide (25 mg/day)+amilorid (2.5 mg/
day) vs. enalapril (10 mg/day) or lisinopril (10 mg/day) vs.
felodipine (2.5 mg/day) or isradipine (2.5 mg/day)
6,614 70 to 84 4 to 6
ALLHAT 2000, 2002
[10,33]
Doxazosine (2 mg/day) vs. chlorthalidone (12.5 mg/day) vs.
amlodipine (2.5 mg/day) vs. lisinopril (10 mg/day)
42,424 > 55 4.9 for chlorthalidone vs.
amlodipine vs. lisinopril.
3.3 (median) for
chlorthalidone vs.
doxazosine
NORDIL 2000 [34] Diltiazem (180 to 360 mg/day) vs. thiazide (not specified) or beta-
blocker (not specified)
10,881 50 to 74 4.5
INSIGHT 2000 [35] Nifedipine (30 mg/day) vs. hydrochlorothiazide (25 mg/day)
+amilorid (2.5 mg/day)
6,321 55 to 80 ~3.5
LIFE 2002 [36] Losartan (50 mg/day) vs. atenolol (50 mg/day) 9,193 55 to 80 4.8
ANBP 2 2003 [37] ACE-inhibitor (unspecified type and dosage) vs. thiazide-diuretic
(unspecified type and dosage)
6,083 65 to 84 4.1
CONVINCE 2003 [38] Verapamil (180 mg/day) vs. atenolol (50 mg/day) or
hydrochlorothiazide (12.5 mg/day)
16,602 > 55 3
HYVET-PILOT 2003
[39]
Lisinopril (2.5 mg/day) vs. bendroflumethiazide (2.5 mg/day) vs. no
treatment
857 > 80 1.1
SHELL 2003 [40] Chlorthalidone (12.5 mg/day) vs. lacidipine (4 mg/day) 1,882 > 60 2.7 (median)
VALUE 2004 [49] Valsartan (80 mg/day) vs. amlodipine (5 mg/day) 15,245 > 50 4.2
E-COST 2005 [41] Candesartan (4 or 8 mg/day) vs. “conventional based regimen” 1,630 35 to 79 3.1
CASE-J 2008 [42] Candesartan (8 mg/day) vs. amlodipine (5 mg/day) 4,703 63.8
(mean)
3.2
HYVET 2008 [48] Indapamid (1.5 mg/day) vs. placebo 3,845 ≥ 80 2.1
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Page 5 of 14“cardiovascular event” and since the exact proportion of
participants with established cardiovascular disease was
difficult to discern from the study reports, we decided
to include these studies.
Synthesis of results
Relative risk estimates and quality of evidence
The various drug-classes and number of studies per
direct comparison included in our network-analysis are
shown in Figure 2.
Tables 3 and 4 display effect estimates for our primary
and secondary outcomes, respectively. The tables also
include the results of the quality assessment of the evi-
dence underlying each effect estimate. We have limited
the tables to include only the most clinically relevant com-
parisons, that is, we have excluded “diuretics and/or beta-
blockers”, “conventional drugs” or “placebo/control”. The
complete presentation is found in Additional files 3 and 4.
A detailed presentation of the quality of evidence assess-
ments is found in Additional file 5.
As expected, the results were favoring active drug
treatment over placebo or no treatment.
For most drug-drug comparisons, we found few signifi-
cant differences, and for most comparisons the quality of
the evidence was rated as low (or very low). Overall, the
results were ambiguous, with no drug-class standing out
as superior across different outcomes.
There was high quality evidence that beta-blockers are
inferior to ARB in terms of total mortality (RR 1.14; 95%
CrI 1.02 to 1.28). Other significant mortality differences
represented only low or very low quality evidence.
The inferiority of ACE-inhibitors to CCB regarding
stroke-risk was significant and based on moderate quality
evidence (RR 1.19; 95% CrI 1.03 to 1.38). Similarly, the
superiority of ACE-inhibitors over CCB with regards to
risk of developing heart failure was also significant and
based on moderate quality evidence (RR 0.82; 95% CrI
0.69 to 0.94).
We found moderate quality evidence that diuretics
reduce the risk of myocardial infarction, compared to
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Figure 2 Direct comparisons in network model.
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Page 6 of 14beta-blockers (RR 0.82; 95% CrI 0.68 to 0.98). Diuretics
were also, based on moderate quality evidence, signifi-
cantly better at reducing the risk of heart failure than
CCB (RR 0.73; 95% CrI 0.62 to 0.84), beta-blockers (RR
0.73; 95% CrI 0.54 to 0.96) and alpha-blockers (RR 0.51;
95% CrI 0.40 to 0.64). Diuretics, however, significantly
increased the risk of diabetes relative to ACE-inhibitors
(RR 1.43; 95% CrI 1.12 to 1.83) and CCB (RR 1.27; 95%
CrI 1.05 to 1.57), based on moderate and high quality evi-
dence, respectively.
Ranking of drug-classes
Consistent with our effect estimates per comparison
(Tables 3 and 4), the findings from our ranking of drug-
classes are ambiguous in the sense that certain drug-
classes were superior for some outcomes, while other
drugs fared better for other outcomes (Table 5).
Consistency of network-model
We did not find any statistically significant inconsistencies
in the network when comparing effect estimates based on
direct vs. indirect evidence. However, there were some
inconsistencies that we should point out (Table 6).
In three instances the inclusion of indirect evidence
shifted the effect estimate from “non-significant” (that is,
the CrI included the value 1) to “significant”,o rv i c e
versa. First, for beta-blockers vs. ARB the direct compari-
son-analysis yielded a significant increased risk of stroke
with beta-blockers (RR 1.34, Crl 1.03 to 1.74), whereas
the result from the MTM did not (RR 1.23, Crl 0.96 to
1.49) (Bayesian P-value for inconsistency = 0.17). Second,
also for beta-blockers vs. ARB, the results for diabetes
incidence based on direct evidence was not significant
(RR.32, Crl 0.97 to 1.82), while in the MTM it was (RR
Table 3 Main findings (primary outcomes).
All-cause mortality Myocardial infarction Stroke
Diuretics vs.BB 0.90 (0.80 to 1.01) 0.82 (0.68 to 0.98) 0.83 (0.68 to 1.07)
⊕⊕⊕O ⊕⊕OO ⊕⊕OO
Diuretics vs. ACE 1.00 (0.93 to 1.08) 1.00 (0.88 to 1.15) 0.94 (0.81 to 1.10)
⊕⊕⊕O ⊕⊕⊕O ⊕⊕⊕O
Diuretics vs. CCB 1.03 (0.96 to 1.10) 0.96 (0.84 to 1.07) 1.12 (0.97 to 1.29)
⊕⊕⊕O ⊕⊕⊕O ⊕⊕OO
Diuretics vs.alpha-blockers 0.98 (0.87 to 1.12) 0.99 (0.80 to 1.23) 0.85 (0.66 to 1.12)
⊕⊕⊕O ⊕⊕⊕O ⊕⊕OO
Diuretics vs.ARB 1.02 (0.92 to 1.14) 0.83 (0.69 to 1.03) 1.02 (0.82 to 1.28)
⊕⊕OO ⊕ OOO ⊕ OOO
BB vs. ACE 1.12 (0.98 to 1.27) 1.22 (1.00 to 1.52) 1.13 (0.86 to 1.42)
⊕ OOO ⊕⊕OO ⊕ OOO
BB vs. CCB 1.14 (1.01 to 1.28) 1.17 (0.97 to 1.42) 1.34 (1.05 to 1.64)
⊕⊕OO ⊕ OOO ⊕⊕OO
BB vs. alpha-blockers 1.09 (0.93 to 1.30) 1.20 (0.92 to 1.61) 1.02 (0.71 to 1.42)
⊕ OOO ⊕ OOO ⊕ OOO
BB vs. ARB 1.14 (1.02 to 1.28) 1.02 (0.84 to 1.27) 1.23 (0.96 to 1.49)
⊕⊕⊕⊕ ⊕⊕⊕O ⊕⊕⊕O
ACE vs. CCB 1.02 (0.95 to 1.10) 0.96 (0.83 to 1.07) 1.19 (1.03 to 1.38)
⊕⊕⊕O ⊕⊕⊕O ⊕⊕⊕O
ACE vs. alpha-blockers 0.98 (0.85 to 1.14) 0.99 (0.77 to 1.27) 0.91 (0.67 to 1.24)
⊕⊕OO ⊕ OOO ⊕ OOO
ACE vs. ARB 1.02 (0.91 to 1.14) 0.84 (0.68 to 1.04) 1.08 (0.86 to 1.37)
⊕⊕OO ⊕ OOO ⊕ OOO
CCB vs. alpha-blockers 0.96 (0.83 to 1.11) 1.03 (0.82 to 1.34) 0.77 (0.57 to 1.04)
⊕⊕OO ⊕ OOO ⊕ OOO
CCB vs. ARB 1.00 (0.91 to 1.10) 0.87 (0.74 to 1.06) 0.91 (0.75 to 1.11)
⊕⊕⊕⊕ ⊕⊕⊕O ⊕⊕⊕O
Alpha-blockers vs. ARB 1.04 (0.88 to 1.23) 0.84 (0.63 to 1.14) 1.20 (0.85 to 1.69)
⊕⊕OO ⊕ OOO ⊕ OOO
ACE, Angiotensin Converting Enzyme Inhibitors; ARB, Angiotensin Receptor Blockers; BB, Beta-blockers; CCB, Calcium Channel Blockers; ⊕⊕⊕⊕ , High quality
evidence; ⊕⊕⊕O, Moderate quality evidence; ⊕⊕OO, Low quality evidence; ⊕ OOO, Very low quality evidence
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Page 7 of 14Table 4 Main findings (secondary outcomes).
Angina Heart failure Diabetes incidence
Diuretics vs. BB 0.96 (0.28 to 5.78) 0.73 (0.54 to 0.96) 1.09 (0.80 to 1.44)
⊕ OOO ⊕⊕⊕O ⊕⊕OO
Diuretics vs. ACE 0.97 (0.42 to 2.51) 0.88 (0.76 to 1.06) 1.43 (1.12 to 1.83)
⊕⊕OO ⊕⊕OO ⊕⊕⊕O
Diuretics vs. CCB 1.05 (0.56 to 2.19) 0.73 (0.62 to 0.84) 1.27 (1.05 to 1.57)
⊕⊕OO ⊕⊕⊕O ⊕⊕⊕⊕
Diuretics vs. alpha-blockers 0.89 (0.31 to 2.52) 0.51 (0.40 to 0.64) -
⊕ OOO ⊕⊕⊕O
Diuretics vs. ARB 0.86 (0.39 to 3.27) 0.80 (0.61 to 0.98) 1.59 (1.23 to 2.12)
⊕ OOO ⊕⊕OO ⊕⊕OO
BB vs. ACE 1.03 (0.17 to 3.76) 1.21 (0.91 to 1.69) 1.31 (0.95 to 1.88)
⊕ OOO ⊕ OOO ⊕ OOO
BB vs. CCB 1.10 (0.23 to 3.31) 1.00 (0.76 to 1.33) 1.17 (0.89 to 1.61)
⊕ OOO ⊕ OOO ⊕ OOO
BB vs. alpha-blockers 0.93 (0.11 to 4.35) 0.69 (0.50 to 1.02) -
⊕ OOO ⊕ OOO
BB vs. ARB 0.88 (0.31 to 2.58) 1.08 (0.86 to 1.38) 1.46 (1.15 to 1.98)
⊕⊕OO ⊕⊕⊕⊕ ⊕⊕⊕⊕
ACE vs. CCB 1.08 (0.48 to 2.44) 0.82 (0.69 to 0.94) 0.89 (0.73 to 1.10)
⊕ OOO ⊕⊕⊕O ⊕⊕OO
ACE vs. alpha-blockers 0.91 (0.22 to 3.42) 0.58 (0.43 to 0.75) -
⊕ OOO ⊕⊕OO
ACE vs. ARB 0.86 (0.35 to 3.50) 0.90 (0.67 to 1.10) 1.11 (0.85 to 1.51)
⊕ OOO ⊕ OOO ⊕ OOO
CCB vs. alpha-blockers 0.85 (0.23 to 2.78) 0.70 (0.53 to 0.92) -
⊕ OOO ⊕⊕OO
CCB vs. ARB 0.81 (0.45 to 2.30) 1.10 (0.87 to 1.31) 1.25 (1.02 to 1.56)
⊕⊕OO ⊕⊕⊕O ⊕⊕⊕⊕
Alpha-blockers vs. ARB 0.95 (0.29 to 5.71) 1.57 (1.09 to 2.12) -
⊕ OOO ⊕⊕OO
ACE, Angiotensin Converting Enzyme Inhibitors; ARB, Angiotensin Receptor Blockers; BB, Beta-blockers; CCB, Calcium Channel Blockers; ⊕⊕⊕⊕ , High quality
evidence; ⊕⊕⊕O, Moderate quality evidence; ⊕⊕OO, Low quality evidence; ⊕ OOO, Very low quality evidence
Table 5 Proportion of times that a drug-class ended up among the top three (in repeated simulations)
Mortality Myocardial infarction Stroke Angina Heart failure Diabetes
Diuretics 18% 79% 46% 33% 99% 1%
BB 1% 2% 3% 38% 10% 9%
ACE 23% 75% 11% 27% 83% 96%
CCB 54% 36% 98% 51% 1% 62%
Alpha-blocker 25% 58% 9% 45% 0% -
ARB 49% 5% 60% 22% 22% 99%
Diuretics and/or BB 84% 45% 71% 22% 65% 33%
“Conventional” 46% 0% 1% - 20% -
ACE, Angiotensin Converting Enzyme Inhibitors; ARB, Angiotensin Receptor Blockers; BB, Beta-blockers; CCB, Calcium Channel Blockers;
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Page 8 of 141.46, Crl 1.15 to 1.98) (Bayesian P-value for inconsistency
=0 . 1 3 ) .T h i r d ,f o rt h ec o m p a r i s o no fA C E - i n h i b i t o r sv s .
placebo the direct evidence-analysis yielded an insignifi-
cant difference for all-cause mortality (RR 1.30, Crl 0.82
to 2.14), which became significant in favor of ACE-inhibi-
tors in the MTM (RR posterior median 0.87, Crl 0.79 to
0.96) (Bayesian P-value for inconsistency = 0.08).
The lowest P-value (0.06) for inconsistency was seen
for all-cause mortality in the diuretics and/or beta-block-
ers vs. placebo-comparison. In this case, both estimates
favored diuretics and/or beta-blockers significantly, but
the effect size estimates differed (direct evidence: RR
0.57, Crl 0.34 to 0.84; MTM: RR 0.82, Crl 0.73 to 0.93).
The absence of clear inconsistencies in the network
suggests that our model is trustworthy, but some caution
is warranted when interpreting the findings that changed
substantially after the inclusion of indirect evidence. The
full table of comparisons between results from MTM and
results based on direct and indirect evidence are shown
in Additional file 6.
Discussion
Summary of evidence
Our analysis is, to date, the most comprehensive analy-
sis of the existing data on the comparative effectiveness
of different antihypertensive drug-classes used in pri-
mary prevention of cardiovascular diseases.
As for most other systematic reviews in this field we find
limited evidence of important differences between the var-
ious drug-classes. The differences we do find are not easy
to put into practice as the ranking of a drug-class depends
on which outcome one chooses to emphasize, and no
drugs are consistently among the best across all important
outcomes.
Our ranking of drug-classes, as presented in Table 5
may be useful to decision makers, or it may add to the
Table 6 Effect estimates from multiple-treatment meta-analysis (MTM) compared to direct and indirect estimates,
based on node-splitting [23]
Outcome MTM-estimate
(95% Crl)
Direct estimate
(95% Crl)
Indirect estimate
(95% Crl)
P-value for
inconsistency
Diuretics vs. beta-blockers Diabetes-
incidence
1.09 0.88 1.31 0.13
(0.80 to 1.44) (0.59 to 1.32) (0.88 to 2.17)
Diuretics vs. ACE-inhibitors Diabetes-
incidence
1.43 1.54 1.25 0.24
(1.12 to 1.83) (1.14 to 2.10) (0.89 to 1.79)
Diuretics vs. placebo All-cause
mortality
0.88 0.89 0.80 0.29
(0.80 to 0.95) (0.82 to 0.97) (0.68 to 0.96)
Beta-blockers vs. ARB Stroke 1.23 1.34 1.00 0.17
(0.96 to 1.49) (1.03 to 1.74) (0.69 to 1.41)
Beta-blockers vs. ARB Diabetes-
incidence
1.46 1.32 1.98 0.13
(1.15 to 1.98) (0.97 to 1.82) (1.26 to 3.40)
ACE- inhibitors vs. CCB All-cause
mortality
1.02 1.05 0.95 0.21
(0.95 to 1.10) (0.96 to 1.13) (0.82 to 1.09)
ACE- inhibitors vs. CCB Heart fail ure 0.82 0.79 0.68 0.29
(0.69 to 0.94) (0.67 to 0.95) (0.52 to 0.90)
ACE-inhibitors vs. placebo All-cause
mortality
0.87 1.30 0.86 0.08
(0.79 to 0.96) (0.82 to 2.14) (0.77 to 0.95)
Diuretics and/or beta-blockers vs.
placebo
All-cause
mortality
0.82 0.57 0.85 0.06
(0.73 to 0.92) (0.34 to 0.84) (0.75 to 0.96)
CCB vs. ARB Stroke 0.91 0.86 1.15 0.19
(0.75 to 1.11) (0.69 to 1.05) (0.78 to 1.70)
CCB vs. ARB Diabetes-
incidence
1.25 1.29 0.86 0.14
(1.02 to 1.56) (1.07 to 1.71) (0.49 to 1.49)
Table is limited to comparisons where Bayesian “P-values” for inconsistency were < 0.3. For a complete overview of MTM-, direct, and indirect estimates see
Additional file 6
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Page 9 of 14confusion. By presenting the chance that a drug is among
the top three for an outcome, we had hoped that one or
two drugs would emerge as first choice candidates by
being among the three best drugs across several impor-
tant outcomes. However, no such pattern appeared. We
should also point out that the quality of the underlying
evidence is not taken into consideration in the ranking,
thus the results should be interpreted cautiously, and in
conjunction with the drug-comparison findings (Tables 3
and 4).
Beta-blockers (atenolol) were inferior to all drug-classes
for all primary outcomes, and although the difference in
many cases was non-significant and the quality of the evi-
dence was mixed, this may be seen as evidence against
opting for these drugs as the first choice. Beta-blockers
and alpha-blockers were the only drug-classes that were
not significantly superior toa n yd r u g ,f o ra n yo u t c o m e ,
which could suggest not recommending these as first line
medication.
Clinical inferences
Successful management of hypertension is dependent on
many factors, and choice of drug class is one that seems to
be of limited importance. Thus, clinicians should probably
focus more on issues such as limiting adverse events,
improving adherence and better follow up of patients
rather than on which drug to select. However, there is
considerable variation in costs across different antihyper-
tensive agents, thus cost-effectiveness assessments may be
important for decisions about choice of medications.
Our findings in relation to other systematic reviews
Other research groups have conducted network meta-ana-
lyses in this field before us, but our contribution adds
important dimensions. First, some reviewers have only
included one clinical outcome, while we included six clini-
cally important ones. Second, others have reported only
on selected drug-drug comparisons [8,56], rather than the
full range of competing options. Third, a weakness across
earlier reviews of the comparative effectiveness of different
antihypertensive drugs is that they have not included an
explicit assessment of the quality of the evidence backing
the reported effect estimates. An important exception is
the systematic review that informed the recently updated
guidance from the National Institute of Health and Clini-
cal Excellence (NICE), but their effect-estimates were
based on the traditional, not the network meta-analytical
approach [9,57].
Although disagreements between our findings and
those of other systematic reviews are few and relatively
minor, the conclusions drawn by authors vary somewhat
[5,6,8,9,12-14,56,58,59].
In two recent network analyses on the effectiveness of
antihypertensive drugs, the authors limited their analysis
to one outcome: heart failure [14] and diabetes inci-
dence [13]. Despite slightly different study inclusion
criteria, their effect estimates are very similar to ours.
The systematic review and network meta-analysis by
Psaty and colleagues only included comparisons against
diuretics, not between other types of antihypertensive
drugs [8]. A network analysis by Aursnes and colleagues,
also from 2003, focussed on comparing ACE-inhibitors
and CCB, and was limited to three outcomes [56]. Our
findings are not in full agreement with these two earlier
reports, presumably due to our more strict inclusion cri-
teria and perhaps also to the inclusion of results from
more recent studies.
Law and colleagues authored a recent comprehensive
review and meta-analysis on antihypertensive drug treat-
ment [6]. They conducted traditional meta-analyses, with-
out the network approach. Their conclusion was that “all
the classes of blood pressure lowering drugs have a similar
effect in reducing CHD (coronary heart disease) effects
and stroke”. This is close to, but not entirely in agreement
with our findings, which may be due to some of the fol-
lowing issues. First, they elected to compare each drug
class with the pooled results from all other drug classes,
for example, beta-blockers versus all non-beta-blockers.
This analytical approach can be misleading because favor-
able effects from one non-beta-blocker may be off-set by
unfavorable effects from another non-beta-blocker drug-
class. Second, they included trials where high dose diure-
tics were used. This may be misleading as there are good
reasons to believe that high dose diuretics lead to less
favorable outcomes than low dose diuretics [7]. Conse-
quently, as high dose diuretics were used in many of the
trials comparing beta-blockers and diuretics, beta-blockers
came out more favorably in their analyses than they prob-
ably should. Third, in two studies included in their analysis
the participants were randomised to either active drug or
placebo [54,55], and these should, therefore, not be classi-
fied as drug comparison studies, in our view. Fourth, they
did not explicitly assess the quality of the evidence under-
lying their effect-estimates, which is essential for judge-
ments about how confident we can be about the validity of
the findings. Last, they included two studies we classified
as non-randomised trials [60,61].
Limitations
Systematic reviews, as other types of research, are inevi-
tably based on subjective judgements. The assessments
were, however, done by at least two reviewers, making
misjudgements less likely, but still possible.
Although the process of grading the quality of the evi-
dence was done using a structured approach (GRADE),
the assessments are strongly influenced by our judge-
ments. The merit of the GRADE-system is that these jud-
gements are made explicit and accounted for.
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Page 10 of 14As with other research activities, systematic reviews do
not provide answers to questions not asked by the authors.
We have selected the interventions and outcomes we con-
sidered most important, but there are undoubtedly other
aspects that are important for decision-making in this
field. We have, for example, not reviewed the side-effect
profiles of the different drug-classes (except for incidence
of diabetes). Our selection of outcomes is also debatable.
We chose to emphasize what we considered the most
important clinical outcomes and disregarded others that
may be of key interest, such as intermittent claudication,
vascular dementia, renal disease and retinal disease.
A fundamental challenge with the use of meta-analysis is
to judge whether two or more studies are sufficiently simi-
lar to have their results pooled in one analysis. Our judge-
ments regarding this could be criticized. It is, for instance,
not obvious that drugs from the same drug-class are
equivalent, as we have implicitly assumed [11,62]. We had
specifically planned to conduct a separate analysis where
we excluded trials of beta-blockers that had used the agent
atenolol, since the appropriateness of using atenolol as a
comparator-drug has been questioned [11]. However, ate-
nolol was used in all the beta-blocker trials we included in
our review, so an analysis of non-atenolol beta-blockers
could not be done. Similarly, our handling of calcium
channel blockers as an entity can be questioned. The phar-
macological properties vary across these drugs, and it
could be argued that they should be grouped according to
property and not as an entity [63].
In a network analysis like ours, it is assumed that all the
included trials are sufficiently homogeneous to allow for
the combining of all the study findings into one analysis.
This assumption is difficult to validate. Differences in
study populations can, in particular, distort estimates for
the effects on total mortality, since these are related to the
proportion of deaths that are due to cardiovascular dis-
eases, for each study. We did not formally assess how
comparable the various populations were. However, our
use of relatively strict inclusion criteria, for example,
including only studies where the majority of participants
had no prior cardiovascular event and excluding studies of
specific high-risk groups, substantiates that the popula-
tions were somewhat similar. Also, the finding that the
effect-estimates from the network analysis were similar to
the estimates from the direct comparisons provides some
evidence that the trials were reasonably homogeneous.
The definitions of outcomes vary from study to study,
for instance, regarding heart failure. Study reports are not
always clear with respect to whether the number of
patients with events or the total number of events were
counted. We believe such differences across studies has
had limited influence on our overall findings.
Our objective was to estimate the relative risk reduc-
tion for different antihypertensive drugs in individuals
without cardiovascular disease (primary prevention).
However, we chose to include studies where up to half
the participants had experienced a cardiovascular event
(secondary prevention). Our reasoning was that such
studies contain information of relevance to our research
question. This is in accordance with the approach used
by the World Health Organization when they prepared
their most recent guidelines on primary prevention of
cardiovascular diseases [64]. In several earlier reviews on
antihypertensive treatment the authors have included
studies where all participants were patients with cardio-
vascular disease. This is clearly valid if the relative effect
of using antihypertensive medication is the same for
healthy and for sick people, and Law and colleagues do
provide some data to support such a view [6]. Our
choice to exclude such trials may thus be criticized. On
the other hand, it is not firmly established that the rela-
tive treatment effect of antihypertensive medication is
constant across different patient groups. And even if
this proves to be the case it is still conceivable that dif-
ferent types of medication may work differently for peo-
ple with and without cardiovascular disease, something
for which Law and colleagues also found evidence [6].
Our meta-analyses are based on a count of events at
one moment in time, that is, at the end of each trial.
This analytic approach is not entirely valid unless the
relative effect size is constant over time. A more com-
plex analysis, including time to events, would require
access to more data from each study than what was
available to us.
The majority of the included trials in this review were
sponsored by companies with a vested interest in the
study results. Such sponsorship has been associated with
bias in favour of the product made by the funding com-
pany [65]. Possible explanations include publication bias
and use of inappropriate comparators. Limiting our review
to large-scale studies should reduce risk of publication
bias or other forms of selective reporting [20]. Whether
the most appropriate comparator drug has been selected
is more difficult to assess. Biased analyses were minimized
in our review because we based our effect-estimates on
actual figures presented in the various articles, rather than
relying on the analyses conducted by the study-authors
and/or sponsors.
Future research agenda
Despite the fact that many methodologically sound large-
scale trials of anti-hypertensive drugs have been con-
ducted, our confidence in the overall findings ranged
from very low to high after assessing the quality of the
evidence using the GRADE-instrument. This means that
the results from future trials may alter our conclusions.
Future research to improve the quality of hypertension
management should also focus on other issues, such as
Fretheim et al. BMC Medicine 2012, 10:33
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Page 11 of 14interventions to improve treatment adherence and on
how to organise follow-up of patients more effectively.
Conclusions
Based on the available evidence, there seems to be little
or no difference between commonly used blood pressure
lowering medications with regards cardiovascular risk
reduction. Beta-blockers (atenolol) and alpha-blockers
are the only drug-classes that were not significantly
superior to any other drugs, for any outcome, and may
thus not be prime candidates for first-line antihyperten-
sive treatment.
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the various electronic databases that were searched to identify relevant
randomized controlled trials.
Additional file 2: Table of excluded studies. Contains a list of studies
that were excluded from the review, mostly after reading the full text
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